Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial

We report results of the 20-patient safety run-in.

Source: European Journal of Cancer - December 3, 2020 Category: Cancer & Oncology Authors: Alice Boil ève, Marc Hilmi, Paul Gougis, Romain Cohen, Benoît Rousseau, Jean-Frédéric Blanc, Meher Ben Abdelghani, Hélène Castanié, Laëtitia Dahan, David Tougeron, Jean-Philippe Metges, Christophe Tournigand, Marie-Line Garcia-Larnicol, Dewi Verne Tags: Original Research Source Type: research